Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial PharmaphorumRoche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.OncologyRead full story pharminent July 2, 2026 (Last updated: July 2, 2026) Pharmaphorum Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib. Oncology Read full story Post navigation Previous: Insilico Medicine, Takeda partner on AI-driven drug discoveryNext: AZ forges ever-closer ties with China’s CSPC Pharma Related Stories Clinical Data Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts pharminent September 2, 2026 Clinical Data Novartis says MS pill succeeds in two large studies pharminent September 1, 2026 Clinical Data ESC 2026: Evolocumab explores new frontiers in CV disease prevention pharminent August 31, 2026